Remicade's psoriasis advantage

Remicade infliximab looks to be more than twice as effective as other biologics marketed to treat moderate to severe plaque psoriasis, based on data published intheLancetearlier this month. The only drug for which similarly robust data have been published is Humira adalimumab. Why the differences are so stark isn't clear, but at least in the case of the anti-TNFs, it could have to do with the way each binds TNF alpha.

As published, the low dose of Remicade given less frequently than the other treatments resulted in 80% of patients achieving a PASI 75 score. Similar results have been reported for Humira, which is marketed by Abbott Laboratories (ABT, Abbott Park, Ill.) to treat rheumatoid and psoriatic arthritis but is not approved to treat psoriasis (see "Passing the PASI Test"). ...